Research graph
References from Immunologic Consequences of Genomic Instabilities. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
10.1126/science.aaa1348 · 2015 · External reference
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
10.1126/science.aan6733 · 2017 · External reference
Genomic correlates of response to immune checkpoint blockade
10.1038/s41591-019-0382-x · 2019 · External reference
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
10.1126/science.aaf8399 · 2017 · External reference
TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes
10.1073/pnas.1500973112 · 2015 · External reference
Neoantigen dissimilarity to the self-proteome predicts immunogenicity and response to immune checkpoint blockade
10.1016/j.cels.2019.08.009 · 2019 · External reference
Genetic basis for clinical response to CTLA-4 blockade in melanoma
10.1056/nejmoa1406498 · 2014 · External reference
Therapeutic targeting of mismatch repair-deficient cancers
10.1038/s41571-025-01054-6 · 2025 · External reference
Neoantigens in cancer immunotherapy
10.1126/science.aaa4971 · 2015 · External reference
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
10.1038/s41416-018-0220-9 · 2018 · External reference
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
10.1038/nature24673 · 2017 · External reference
Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response
10.1126/science.aau0447 · 2019 · External reference
PD-1 blockade in solid tumors with defects in polymerase epsilon
10.1158/2159-8290.cd-21-0521 · 2022 · External reference
Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity
10.1038/s41588-022-01108-w · 2022 · External reference
Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
10.1016/j.annonc.2024.03.009 · 2024 · External reference
DNA polymerase and mismatch repair exert distinct microsatellite instability signatures in normal and malignant human cells
10.1158/2159-8290.cd-20-0790 · 2021 · External reference
Evaluating the utility of tumour mutational signatures for identifying hereditary colorectal cancer and polyposis syndrome carriers
10.1136/gutjnl-2019-320462 · 2021 · External reference
Pan-cancer interrogation of MUTYH variants reveals biallelic inactivation and defective base excision repair across a spectrum of solid tumors
10.1200/po.23.00251 · 2024 · External reference
Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer
10.1007/s10637-019-00842-z · 2020 · External reference
Germline MBD4 deficiency causes a multi-tumor predisposition syndrome
10.1016/j.ajhg.2022.03.018 · 2022 · External reference
Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors
10.1038/s41467-018-04322-5 · 2018 · External reference
MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients
10.1016/j.ejca.2022.06.033 · 2022 · External reference
Positive association between location of melanoma, ultraviolet signature, tumor mutational burden, and response to anti-PD-1 therapy
2021 · External reference
Role of ultraviolet mutational signature versus tumor mutation burden in predicting response to immunotherapy
10.1002/1878-0261.12748 · 2020 · External reference
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
10.1016/j.cell.2021.01.002 · 2021 · External reference
The immune landscape of cancer
10.1016/j.immuni.2018.03.023 · 2018 · External reference
On the origin of G T transversions in lung cancer
2003 · External reference
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations
10.21037/tlcr-20-559 · 2021 · External reference
Mutational signatures of ionizing radiation in second malignancies
10.1038/ncomms12605 · 2016 · External reference
Emerging evidence for adapting radiotherapy to immunotherapy
10.1038/s41571-023-00782-x · 2023 · External reference
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
10.1038/ncomms15618 · 2017 · External reference
The mutational footprints of cancer therapies
10.1038/s41588-019-0525-5 · 2019 · External reference
Genomic, pathway network, and immunologic features distinguishing squamous carcinomas
10.1016/j.celrep.2018.03.063 · 2018 · External reference
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer
10.1038/s41467-017-02320-7 · 2017 · External reference
Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O6-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: the MAYA trial
10.1200/jco.21.02583 · 2022 · External reference
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients
10.1158/2159-8290.cd-21-1434 · 2022 · External reference
Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer
10.1016/j.ccell.2025.05.010 · 2025 · External reference
Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models
10.1016/j.ccell.2025.05.014 · 2025 · External reference
Acquired high tumor mutational burden and activity of immunotherapy after targeted therapy in microsatellite stable colorectal cancer
10.1158/1078-0432.ccr-25-2566 · 2026 · External reference
Mechanisms and therapeutic implications of hypermutation in gliomas
10.1038/s41586-020-2209-9 · 2020 · External reference
Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
2022 · External reference
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
10.1126/science.aaf1490 · 2016 · External reference
Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer
10.1016/j.cell.2018.03.022 · 2018 · External reference
Profound tissue specificity in proliferation control underlies cancer drivers and aneuploidy patterns
10.1016/j.cell.2018.02.037 · 2018 · External reference
Genomic and functional approaches to understanding cancer aneuploidy
10.1016/j.ccell.2018.03.007 · 2018 · External reference
Ongoing genome doubling shapes evolvability and immunity in ovarian cancer
10.1038/s41586-025-09240-3 · 2025 · External reference
Clonal evolution in breast cancer revealed by single nucleus genome sequencing
10.1038/nature13600 · 2014 · External reference
Allele-specific HLA loss and immune escape in lung cancer evolution
10.1016/j.cell.2017.10.001 · 2017 · External reference
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
10.1038/s41588-018-0200-2 · 2018 · External reference
Identification of a group of 9-amino-acridines that selectively downregulate regulatory T cell functions through FoxP3
10.1016/j.isci.2025.111931 · 2025 · External reference
Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma
10.4049/jimmunol.169.3.1611 · 2002 · External reference
Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing
10.1038/s41588-019-0576-7 · 2020 · External reference
Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity
10.1038/nature21356 · 2017 · External reference
Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma
10.1038/ng.2295 · 2012 · External reference
Paradoxical relationship between chromosomal instability and survival outcome in cancer
10.1158/0008-5472.can-10-3667 · 2011 · External reference
cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers
10.1038/s41586-022-04847-2 · 2022 · External reference
Non-cell-autonomous cancer progression from chromosomal instability
10.1038/s41586-023-06464-z · 2023 · External reference
Chromosomal instability drives metastasis through a cytosolic DNA response
10.1038/nature25432 · 2018 · External reference
Epigenetic and transcriptional control of the epidermal growth factor receptor regulates the tumor immune microenvironment in pancreatic cancer
10.1158/2159-8290.cd-20-0519 · 2021 · External reference
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis
10.1126/sciadv.aeb1611 · 2026 · External reference
Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial
10.1093/annonc/mdv178 · 2015 · External reference
Signatures of copy number alterations in human cancer
10.1038/s41586-022-04738-6 · 2022 · External reference
A compendium of mutational cancer driver genes
10.1038/s41568-020-0290-x · 2020 · External reference
Ordered and deterministic cancer genome evolution after p53 loss
10.1038/s41586-022-05082-5 · 2022 · External reference
Living in CIN: mitotic infidelity and its consequences for tumor promotion and suppression
10.1016/j.devcel.2016.10.023 · 2016 · External reference
Melanomas and mechanical stress points on the plantar surface of the foot
10.1056/nejmc1512354 · 2016 · External reference
Defining stem cell dynamics in models of intestinal tumor initiation
10.1126/science.1243148 · 2013 · External reference
A gene-environment-induced epigenetic program initiates tumorigenesis
10.1038/s41586-020-03147-x · 2021 · External reference
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
10.1172/jci73531 · 2014 · External reference
Mutant p53 exploits enhancers to elevate immunosuppressive chemokine expression and impair immune checkpoint inhibitors in pancreatic cancer
10.1016/j.immuni.2025.06.005 · 2025 · External reference
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities
10.1158/2159-8290.cd-14-1236 · 2015 · External reference
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
10.1016/j.ebiom.2020.102990 · 2020 · External reference
Fundamental immune–oncogenicity trade-offs define driver mutation fitness
10.1038/s41586-022-04696-z · 2022 · External reference
Repair pathway choices and consequences at the double-strand break
10.1016/j.tcb.2015.07.009 · 2016 · External reference
Signatures of mutational processes in human cancer
10.1038/nature12477 · 2013 · External reference
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation
10.1158/0008-5472.can-12-1470 · 2012 · External reference
Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents
10.1158/2159-8290.cd-11-0206 · 2012 · External reference
Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
10.1371/journal.pone.0215381 · 2019 · External reference
Copy-number signatures and mutational processes in ovarian carcinoma
10.1038/s41588-018-0179-8 · 2018 · External reference
TCR clonality and genomic instability signatures as prognostic biomarkers in high grade serous ovarian cancer
10.3390/cancers13174394 · 2021 · External reference
Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy
10.1038/s43018-020-00139-8 · 2021 · External reference
Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer
10.1038/s43018-024-00876-0 · 2025 · External reference
Homozygous co-deletion of type I interferons and CDKN2A genes in thoracic cancers: potential consequences for therapy
10.3389/fonc.2021.695770 · 2021 · External reference
All is not lost: learning from 9p21 loss in cancer
10.1016/j.it.2022.03.003 · 2022 · External reference
FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma
10.1007/s10014-023-00473-6 · 2024 · External reference
Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels
10.1371/journal.pone.0046088 · 2012 · External reference
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study
10.1182/blood-2009-10-247122 · 2010 · External reference
Interferon epsilon loss is elusive 9p21 link to immune-cold tumors, resistant to immune checkpoint therapy, and endogenous CXCL9/10 induction
10.1016/j.jtho.2024.12.020 · 2025 · External reference
Genomic instability and protumoral inflammation are associated with primary resistance to anti-PD-1 + antiangiogenesis in malignant pleural mesothelioma
10.1158/2159-8290.cd-22-0886 · 2023 · External reference
Tumor aneuploidy predicts survival following immunotherapy across multiple cancers
10.1038/s41588-022-01235-4 · 2022 · External reference
Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair
10.1038/s41467-018-04002-4 · 2018 · External reference
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency
10.1038/s41591-021-01581-6 · 2022 · External reference
Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels
10.1016/j.esmoop.2022.100540 · 2022 · External reference
Efficient variant set mixed model association tests for continuous and binary traits in large-scale whole-genome sequencing studies
10.1016/j.ajhg.2018.12.012 · 2019 · External reference
Clinical outcomes in non-small-cell lung cancer patients treated with EGFR-tyrosine kinase inhibitors and other targeted therapies based on tumor versus plasma genomic profiling
2021 · External reference
Concurrent tissue and circulating tumor DNA molecular profiling to detect guideline-based targeted mutations in a multicancer cohort
10.1001/jamanetworkopen.2023.51700 · 2024 · External reference
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
10.1038/s41591-022-01754-x · 2022 · External reference
Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency status
10.1001/jamaoncol.2018.4942 · 2019 · External reference
Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer
10.1056/nejmoa2402141 · 2024 · External reference
An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes
10.1038/s41379-021-00918-3 · 2022 · External reference
Efficacy of immunotherapy in gastrointestinal (GI) tumors with mismatch repair deficient (MMRd) unusual phenotype: an AGEO real-world study
10.1136/jitc-2024-011436 · 2025 · External reference
Gene-specific outcomes in patients with Lynch syndrome treated by immune checkpoint blockade for advanced cancer
10.1200/jco.2025.43.16_suppl.10504 · 2025 · External reference
Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
10.1056/nejmoa2017699 · 2020 · External reference
Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer
10.1016/j.esmoop.2021.100120 · 2021 · External reference
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
10.1002/path.6279 · 2024 · External reference
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial
10.1038/s43018-024-00894-y · 2025 · External reference
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
10.1038/s41588-018-0312-8 · 2019 · External reference
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
10.1016/s1470-2045(20)30445-9 · 2020 · External reference
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
10.1136/jitc-2019-000147 · 2020 · External reference
The spectrum of benefit from checkpoint blockade in hypermutated tumors
10.1056/nejmc2031965 · 2021 · External reference
Tumour evolution inferred by single-cell sequencing
10.1038/nature09807 · 2011 · External reference
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers
10.1038/ng1861 · 2006 · External reference
Nonoperative management of mismatch repair-deficient tumors
10.1056/nejmoa2404512 · 2025 · External reference
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
10.1038/s41591-020-0805-8 · 2020 · External reference
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
10.1016/s0140-6736(24)02848-4 · 2025 · External reference
Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study
10.1136/jitc-2023-008689 · 2024 · External reference
A frameshift peptide neoantigen-based vaccine for mismatch repair-deficient cancers: a phase I/IIa clinical trial
10.1158/1078-0432.ccr-19-3517 · 2020 · External reference
Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies
10.1136/jitc-2024-011177 · 2025 · External reference
Dostarlimab for primary advanced or recurrent endometrial cancer
10.1056/nejmoa2216334 · 2023 · External reference
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study
10.1007/s00262-020-02688-4 · 2021 · External reference
Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50
10.1200/jco.21.00174 · 2021 · External reference
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
10.1093/annonc/mdz127 · 2019 · External reference
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
10.1016/s0140-6736(19)32591-7 · 2019 · External reference
Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma
10.1056/nejmoa2407417 · 2025 · External reference
Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update
10.1016/j.ejca.2025.115547 · 2025 · External reference
479MO Phase I/II clinical investigation of invikafusp alfa, a first-in-class TCR-beta chain-targeted bispecific antibody, as monotherapy in patients with anti-PD(L)1-resistant, antigen-rich gastrointestinal (GI) cancers
10.1016/j.annonc.2025.05.496 · 2025 · External reference
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study
10.1093/annonc/mdz135 · 2019 · External reference
PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness
10.1158/0008-5472.can-18-1003 · 2019 · External reference
814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)
10.1016/j.annonc.2020.08.953 · 2020 · External reference
Abstract CT004: KEYLYNK-007: tumor agnostic trial of olaparib plus pembrolizumab in homologous recombination repair mutation- and homologous recombination deficiency- positive advanced cancers
10.1158/1538-7445.am2025-ct004 · 2025 · External reference
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
10.1001/jamaoncol.2019.1029 · 2019 · External reference
Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
10.1001/jamaoncol.2019.1048 · 2019 · External reference
ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer
10.1126/sciadv.ado4618 · 2024 · External reference
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
10.1038/s41591-024-02808-y · 2024 · External reference
Small-molecule inhibition of kinesin KIF18A reveals a mitotic vulnerability enriched in chromosomally unstable cancers
10.1038/s43018-023-00699-5 · 2024 · External reference
Exclusion of persistent mutations in splicing factor genes and isocitrate dehydrogenase 2 improves the prognostic power of molecular measurable residual disease assessment in acute myeloid leukemia
10.3324/haematol.2023.283510 · 2024 · External reference
Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma
10.1200/jco.20.03167 · 2021 · External reference
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial
10.1038/s41591-025-03575-0 · 2025 · External reference
Rezatapopt (PC14586): a first-in-class small molecule p53 Y220C mutant protein stabilizer in clinical trials
10.1021/acs.jmedchem.5c00670 · 2025 · External reference
Restoration of the tumor suppressor function of Y220C-mutant p53 by rezatapopt, a small-molecule reactivator
10.1158/2159-8290.cd-24-1421 · 2025 · External reference
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity
10.1016/j.ccell.2021.06.018 · 2021 · External reference
TREX1 inactivation unleashes cancer cell STING-interferon signaling and promotes antitumor immunity
10.1158/2159-8290.cd-23-0700 · 2024 · External reference
Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade
10.1158/2159-8290.cd-20-0812 · 2021 · External reference
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients
10.1126/science.adf1329 · 2024 · External reference
High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy
10.1016/j.ejca.2022.08.034 · 2022 · External reference
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
10.1136/jitc-2020-000842 · 2020 · External reference
CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy
10.1016/j.xcrm.2022.100878 · 2023 · External reference
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
10.1038/s41591-020-0856-x · 2020 · External reference
Improved prediction of immune checkpoint blockade efficacy across multiple cancer types
10.1038/s41587-021-01070-8 · 2022 · External reference
Tumor mutational burden and response rate to PD-1 inhibition
10.1056/nejmc1713444 · 2017 · External reference
MBD4-associated neoplasia syndrome: screening of cases with suggestive phenotypes
10.1038/s41431-023-01418-5 · 2023 · External reference
Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures
10.1038/s41467-022-30916-1 · 2022 · External reference
Pan-cancer landscape of homologous recombination deficiency
10.1038/s41467-020-19406-4 · 2020 · External reference
